Vascular endothelial growth factor, stromal growth factor 1α and endothelial progenitor cells in essential thrombocythemia – is there a link between angiogenesis and vasculogenesis?

1 Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127(20):2391-405. Search in Google Scholar

2 Thiele J, Kvasnicka HM, Orazi A, Tefferi A, Gisslinger H Essential thrombocythaemia. In: Swelderow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al, editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon:IARC; 2008. p. 48-50. Search in Google Scholar

3 Bieniaszewska M, Hellmann A. Inne przewlekłe nowotwory mieloproliferacyjne. In: Dmoszyńska A, Robak T, Hus I, editors. Podstawy Hematologii. 3^rd ed. Lublin: Czelej. 2015. p. 342-6. Search in Google Scholar

4 Moulard O, Metha J, Fryzek J, Olivares R, Iqbal U, Mesa RA. Epidemiology of myelofibrosis, essential thrombocythemia, and policythemia vera in the Eurpean Union. Eur J Haematol 2013;92(4):289-97. Search in Google Scholar

5 Tefferi A, Vannucchi AM, Barbui T. Essential thrombocythemia treatment algorithm 2018. Blood Canc J 2018;8(1):2. Search in Google Scholar

6 Góra-Tybor J. Nadpłytkowość samoistna. In: Biblioteka czasopisma hematologia 2. Nowotwory mieloproliferacyjne, zespoły mielodysplastyczne i mastocytoza. Gdańsk: Via Medica; 2017. p. 66-75. Search in Google Scholar

7 Prochorec-Sobieszek M, Szumera-Ciećkiewicz A, Szymańska-Giemza O. Diagnostyka różnicowa nadpłytkowości samoistnej. Hematologia 2012;(3):201-10. Search in Google Scholar

8 Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 2014;123(10):1544-51. Search in Google Scholar

9 Lal A. Essential thrombocitosis. Medscape; 2017. Search in Google Scholar

10 Hellmann A, Prejzner W. Nowotwory mieloproliferacyjne i mielodysplastyczne. In: Szczeklik A, Gajewski P. Interna Szczeklika 2018. Kraków: Medycyna Praktyczna; 2018. p. 1779-82. Search in Google Scholar

11 Rajabi M, Mousa SA. The role of angiogenesis in cancer treatment. Biomedicines 2017;5(2):34. Search in Google Scholar

12 Folkman J. Tumor angiogenesis therapeutic implications. N Engl J Med 1971;285(21):1182-6. Search in Google Scholar

13 Nishida N, Yano H, Nishida T, Kamura T, Kojiro M. Angiogenesis in cancer. Vasc Health Risk Manag 2006;2(3):213-9. Search in Google Scholar

14 Risau W. Mechanisms of angiogenesis. Nature 1997;386(6626):671-4. Search in Google Scholar

15 Cleaver O, Krieg PA. Vascular development. In: Rosenthal N, Harvey RP, editors. Heart development and regeneration. Academic Press; 2010. p. 487-528. Search in Google Scholar

16 Sadler TW. Langman Embriologia. Malejczyk J, Kujawa M, editors. Wrocław: Edra Urban & Partner; 2017. p. 410. Search in Google Scholar

17 Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997;275(5302):964-7. Search in Google Scholar

18 Murasawa S, Asahara T. Endothelial progenitor cells for vasculogenesis. Physiology 2005;20(1):36-42. Search in Google Scholar

19 Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001;7(11):1194-201. Search in Google Scholar

20 Laschke MW, Giebels C, Menger MD. Vasculogenesis: a new piece of the endometriosis puzzle. Hum Reprod Update 2011;17(5):628-36. Search in Google Scholar

21 Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999;103(2):159-65. Search in Google Scholar

22 Byrne AM, Bouchier‐Hayes DJ, Harmey JH. Angiogenic and cell survival functions of Vascular Endothelial Growth Factor (VEGF). J Cell Mol Med 2005;9(4):777-94. Search in Google Scholar

23 Balaji S, King A, Crombleholme TM, Keswani SG. The role of endothelial progenitor cells in postnatal vasculogenesis. Implication for therapeutic neovascularization and wounel healing. Adv Wound Care 2013;2(6):283-95. Search in Google Scholar

24 Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011;473(7347):298-307. Search in Google Scholar

25 Ferrara N. VEGF-A: a critical regulator of blood vessel growth. Eur Cytokine Netw 2009;20(4):158-63. Search in Google Scholar

26 Gadomska G, Stankowska K, Boinska J, Ślusarz R, Tylicka M, Michalska M, et al. VEGF-A, sVEGFR-1 and sVEGFR-2 in BCR-ABL negative myeloproliferative neoplasms. Medicina 2017;53(1):34-9. Search in Google Scholar

27 Chen H, Shen YF, Gong F, Yang GH, Jiang YQ, Zhang R. Expression of VEGF and its effect on cell proliferation in patients with chronic myeloid leukemia. Eur Rev Med Pharmacol Sci 2015;19(19):3569-73. Search in Google Scholar

28 Di Raimondo F, Azarro MP, Palumbo GA, Bognato S, Stagno F, Giustolisi GM, et al. Elevated vascular endothelial growth factor (VEGF) serum levels in idiopatic myelofibrosis. Leukemia 2001;15(6):976-80. Search in Google Scholar

29 Trelinski J, Wierzbowska A, Krawczynska A, Sakowicz A, Pietrucha T, et al. Circulating endothelial cells in essential thrombocythemia and polycythemia vera: correlation with JAK2-V617F mutational status, angiogenic factors and coagulation activation markers. Int J Hematol 2010;91(5):792-8. Search in Google Scholar

30 Alonci A, Allegra A, Bellomo G, Penna G, D’Angelo A, Quartarone E, et al. Evaluation of circulating endothelial cells, VEGF and VEGFR2 serum levels in patients with chronic myeloproliferative diseases. Hematol Oncol 2008;26(4):235-9. Search in Google Scholar

31 Ratajczak MZ, Zuba-Surma E, Kucia M, Reca R, Wojakowski W, Ratajczak J, et al. The pleiotropic effects of the SDF-1 – CXCR4 axis in organogenesis regeneration and tumorigenesis. Leukemia 2006;20(1):1915-24. Search in Google Scholar

32 Petit I, Jin D, Rafii S. The SDF-1-CXCR4 signalling pathway: a molecular hub modulating neo-angiogenesis. Trends Immunol 2007;28(7):299-307. Search in Google Scholar

33 Hattori K, Heissig B, Tashiro K , Honjo T, Tateno M, Shieh J-H, et al. Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells. Blood 2001;97(11):3354-60. Search in Google Scholar

34 Bae YK, Kim GH, Lee JCH, Seo BM, Joo KM, Lee G, et al. The Significance of SDF-1α-CXCR4 Axis in in vivo Angiogenic Ability of Human Periodontal Ligament Stem Cells. Mol Cells 2017;40(6):386-92. Search in Google Scholar

35 Yu JX, Huang XF, Lv WM, Ye CS, Peng XZ, Zhang H, et al. Combination of stromal-derived factor-1α and vascular endothelial growth factor genemodified endothelial progenitor cells is more effective for ischemic neovascularization. J Vasc Surg 2009;50(3):608-16. Search in Google Scholar

36 Timmermans F, Plum J, Yöder MC, Ingram DA, Vandekeckhove B, Case J. Endothelial progenitor cells: identity defined? J Cell Mol Med 2009;13(1):87-102. Search in Google Scholar

37 Buxhofer-Ausch V, Steurer M, Sormann S, Schloegl E, Schimetta W, Gisslinger B, et al. Influence of platelet and white blood cell counts on major thrombosis - analysis from a patient registry in essential thrombocythemia. Eur J Haematol 2016;97(6):511-6. Search in Google Scholar

38 Falanga A, Marchetti M, Evangelista V, Vignoli A, Licini M, Balicco M, et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 2000;96(13):4261-6. Search in Google Scholar

39 Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol 2005;33(5):523-30. Search in Google Scholar

40 Dzietczenia J, Kuliczkowski K. The role of JAK2 in essential thrombocythemia. Acta Haematol Pol 2007;38(20):187-94. Search in Google Scholar

41 Nangalia J, Green AR. Myeloproliferative neoplasms: from origins to outcomes. Blood 2017;130(23):2475-83. Search in Google Scholar

42 Medinger M, Skoda R, Gratwohl A, Theocharides A, Buser A, Heim D, et al. Angiogenesis and vascular endothelial growth factor‐/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status. Br J Haematol 2009;146(2):150-7. Search in Google Scholar

43 Medinger M, Passweg J. Angiogenesis in myeloproliferative neoplasms, new markers and future directions. Memo 2014;7:206-10. Search in Google Scholar

44 Gadomska G, Bartoszewska-Kubiak A, Boinska J, Matiakowska K, Ziołkowska K, Haus O, et al. Selected parameters of angiogenesis and the JAK2, CALR, and MPL mutations in patients with essential thrombocythemia. Clin Appl Thromb Hemost 2018;24(7):1056-60. Search in Google Scholar